PH-790 Adoptive Cell Transfer NK cell therapy(Phio Pharmaceuticals)

N/A

Report date: 2022/09/06 18:03:20

Base Information

Drug NamePH-790 Adoptive Cell Transfer NK cell therapy(Phio Pharmaceuticals)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAphios Corporation

China Registration ClassN/A

Develop Information

Active CompaniesAphios Corporation

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A